Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14963064 | 0.92 | ALDH1A1 (0.34) | CA2ALDH1A1TSHRTDP1MAPT | |
| SCHEMBL14584042 | 0.74 | ALDH1A1 (0.44) | CA2ALDH1A1TSHRTDP1MAPT | |
| SCHEMBL24197725 | 0.71 | ALDH1A1 (0.33) | CA2ALDH1A1MAPT | |
| SCHEMBL13249596 | 0.70 | CA2 (0.41) | CA2ALDH1A1TSHRTDP1MAPT | |
| SCHEMBL13249597 | 0.68 | ALDH1A1 (0.37) | CA2ALDH1A1MAPT | |
| SCHEMBL13249600 | 0.67 | ALDH1A1 (0.43) | ALDH1A1TDP1MAPT | |
| SCHEMBL25054987 | 0.66 | CA2 (0.35) | CA2ALDH1A1MAPT | |
| SCHEMBL24126327 | 0.65 | GABRA5 (0.34) | GABRA1 | |
| SCHEMBL13431385 | 0.64 | MAP4K4 (0.37) | CA2ALDH1A1TSHRTDP1SSTR4 | |
| SCHEMBL22015336 | 0.63 | SSTR4 (0.52) | CA2SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023023-A1 | 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF | ASTEX THERAPEUTICS LIMITED (GB) | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230023023-A1 | 4-AMINOBUT-2-ENAMIDE DERIVATIVES AND SALTS THEREOF | KRAS, NRAS, HRAS | CA2 1795/4885ALDH1A1 2807/4885TSHR 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.